SS Innovations International Inc

SS Innovations International Inc(SSII)股票分析

$2.250

-0.114 (-5.06%)收盘时

Loading chart…
最高
2.395
开盘
2.330
成交量加权均价
2.28
成交量
41.02K
市值
—
最低
2.200
成交额
93.59K
企业价值/息税折旧摊销前利润(TTM)
-41.73

SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset.

AI 分析 of SS Innovations International Inc (SSII)

持有

SS Innovations International Inc (SSII) is currently not a good buy due to its significant price decline of 60.18% year-to-date and an RSI of 21.231, indicating it is oversold. Although the company has a promising new CFO with extensive experience and a strong analyst price target of $7, the recent performance and negative earnings trends present substantial risks. The main risk is the negative net income reported in the last quarter, which was -2,661,350 USD, reflecting ongoing financial struggles.

估值指标

SS Innovations International Inc(SSII)当前预期市盈率为 0.00,5 年平均预期市盈率为 0.00。

预期市盈率

严重低估
5 年均值 P/E
0.00
当前P/E
0.00
高估
0.00
低估
0.00

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
-15.45
当前EV/EBITDA
-41.73
高估
6.73
低估
-37.63

预期市销率

合理
5 年均值 P/S
3.24
当前P/S
6.24
高估
7.67
低估
-1.19

Alphio AI 对 SSII 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%SSII

$8.47

情景价格

基

基准

基准 · 50%SSII

$7.13

情景价格

悲

悲观

悲观 · 25%SSII

$6.18

情景价格

事件时间线

2026-10-13 (ET)

09:00:00

SS Innovations Submits Response to FDA Additional Information Request

2026-07-14 (ET)

09:00:00

SS Innovations Appoints Sarah Romano as CFO

2026-05-05 (ET)

09:00:00

SS Innovations Surpasses 10,500 Cumulative Surgeries

2026-05-01 (ET)

16:30:00

SS Innovations Files to Sell 5.02M Shares of Common Stock

16:30:00

SS Innovations Files $150M Mixed Securities Shelf

资讯

SSII 常见问题 —— 由 Alphio AI 解答

SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset. It operates in the Healthcare sector.

SS Innovations International Inc (SSII) is currently not a good buy due to its significant price decline of 60.18% year-to-date and an RSI of 21.231, indicating it is oversold. Although the company has a promising new CFO with extensive experience and a strong analyst price target of $7, the recent performance and negative earnings trends present substantial risks. The main risk is the negative net income reported in the last quarter, which was -2,661,350 USD, reflecting ongoing financial struggles.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易